EHMT2 and breast cancer: Notably, a recent study by Tu et al. showed that EHMT2 interacts with c-MYC to drive transcriptional repression and tumorigenesis in breast cancer, and that EHMT2 inhibition was a potent suppressor of MYC-dependent tumor growth [30].